Base de dados : MEDLINE
Pesquisa : D12.776.157.125.750.625 [Categoria DeCS]
Referências encontradas : 2322 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 233 ir para página                         

  1 / 2322 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29444082
[Au] Autor:Khan MI; Su YK; Zou J; Yang LW; Chou RH; Yu C
[Ad] Endereço:National Tsing Hua University, Chemistry Department, Hsinchu, Taiwan.
[Ti] Título:S100B as an antagonist to block the interaction between S100A1 and the RAGE V domain.
[So] Source:PLoS One;13(2):e0190545, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Ca2+-binding human S100A1 protein is a type of S100 protein. S100A1 is a significant mediator during inflammation when Ca2+ binds to its EF-hand motifs. Receptors for advanced glycation end products (RAGE) correspond to 5 domains: the cytoplasmic, transmembrane, C2, C1, and V domains. The V domain of RAGE is one of the most important target proteins for S100A1. It binds to the hydrophobic surface and triggers signaling transduction cascades that induce cell growth, cell proliferation, and tumorigenesis. We used nuclear magnetic resonance (NMR) spectroscopy to characterize the interaction between S100A1 and the RAGE V domain. We found that S100B could interact with S100A1 via NMR 1H-15N HSQC titrations. We used the HADDOCK program to generate the following two binary complexes based on the NMR titration results: S100A1-RAGE V domain and S100A1-S100B. After overlapping these two complex structures, we found that S100B plays a crucial role in blocking the interaction site between RAGE V domain and S100A1. A cell proliferation assay WST-1 also supported our results. This report could potentially be useful for new protein development for cancer treatment.
[Mh] Termos MeSH primário: Antígenos de Neoplasias/metabolismo
Proteínas Quinases Ativadas por Mitógeno/metabolismo
Subunidade beta da Proteína Ligante de Cálcio S100/fisiologia
Proteínas S100/metabolismo
[Mh] Termos MeSH secundário: Cálcio/metabolismo
Seres Humanos
Interações Hidrofóbicas e Hidrofílicas
Ressonância Magnética Nuclear Biomolecular
Ligação Proteica
Transdução de Sinais
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antigens, Neoplasm); 0 (S100 Calcium Binding Protein beta Subunit); 0 (S100 Proteins); 0 (S100A1 protein); 0 (S100B protein, human); EC 2.7.11.22 (MOK protein, human); EC 2.7.11.24 (Mitogen-Activated Protein Kinases); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190545


  2 / 2322 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29222857
[Au] Autor:Duda I; Krzych L; Jedrzejowska-Szypulka H; Lewin-Kowalik J
[Ad] Endereço:Department of Anesthesiology and Intensive Care, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
[Ti] Título:Serum levels of the S100B protein and neuron-specific enolase are associated with mortality in critically ill patients.
[So] Source:Acta Biochim Pol;64(4):647-652, 2017.
[Is] ISSN:1734-154X
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Evaluation of the prognostic potential of the S100B protein and neuron-specific enolase (NSE) as predictors of mortality in critically ill patients in intensive care units (ICU). MATERIALS AND METHODS: The study was conducted on 62 patients. Basic clinical variables and blood samples for S100B and NSE level testing were obtained during the first four days after admission. Mortality was described as the patient's death during hospitalization in the ICU. RESULTS: 35% of the patients had died. The level of S100B and NSE was significantly higher in non-survivors in comparison with survivors (p=0.007 and p=0.02, respectively). Mortality risk was significantly higher in patients with higher levels of biomarkers than the reference values for S100B (OR 9.00; 95% CI 2.38-33.99; p<0.001) as well as for NSE (OR 5.75; 95%CI 1.31-25.27; p=0.016). Receiver operating characteristic proved that S100B is a better mortality predictor than NSE (AUC 0.76 for S100B and 0.68 for NSE). From all the other variables, the Apache II score turned out to be the only significant predictor of mortality (AUC 0.88). CONCLUSION: There is a significant correlation between mortality in the ICU and increased serum concentration of S100B and NSE. This correlation is stronger for S100B. Testing for serum levels of S100B and NSE may be useful for prediction of treatment outcomes in the ICU patients.
[Mh] Termos MeSH primário: Biomarcadores/sangue
Estado Terminal
Fosfopiruvato Hidratase/sangue
Subunidade beta da Proteína Ligante de Cálcio S100/sangue
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Unidades de Terapia Intensiva
Masculino
Meia-Idade
Mortalidade
Estudos Prospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Biomarkers); 0 (S100 Calcium Binding Protein beta Subunit); 0 (S100B protein, human); EC 4.2.1.11 (Phosphopyruvate Hydratase)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171210
[St] Status:MEDLINE
[do] DOI:10.18388/abp.2017_1619


  3 / 2322 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27772534
[Au] Autor:Keshavarz M
[Ad] Endereço:Shiraz Neuroscience Research Center,Shiraz University of Medical Sciences,Shiraz,Iran.
[Ti] Título:Glial cells as key elements in the pathophysiology and treatment of bipolar disorder.
[So] Source:Acta Neuropsychiatr;29(3):140-152, 2017 Jun.
[Is] ISSN:1601-5215
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The exact pathophysiology of bipolar disorder (BD) is not yet fully understood, and there are many questions in this area which should be answered. This review aims to discuss the roles of glial cells in the pathophysiology of BD and their contribution to the mechanism of action of mood-stabilising drugs. METHODS: We critically reviewed the most recent advances regarding glial cell roles in the pathophysiology and treatment of BD and the neuroprotective and neurotrophic effects of these cells. RESULTS: Postmortem studies revealed a decrease in the glial cell number or density in the specific layers of prefrontal and anterior cingulate cortex in the patients with BD, whereas there was no difference in other brain regions, such as entorhinal cortex, amygdala and hippocampus. Astrocytes and oligodendrocytes were the most important glial types that were responsible for the glial reduction, but microglia activation rather than loss may be implicated in BD. The decreased number or density of glial cells may contribute to the pathological changes observed in neurons in the patients with BD. Alteration of specific neurotrophic factors such as glial cell line-derived neurotrophic factor and S100B may be an important feature of BD. Glial cells mediate the therapeutic effects of mood-stabilising agents in the treatment of BD. CONCLUSION: Recent studies provide important evidence on the impairment of glial cells in the pathophysiology and treatment of BD. However, future controlled studies are necessary to elucidate different aspects of glial cells contribution to BD, and the mechanism of action of mood-stabilising drugs.
[Mh] Termos MeSH primário: Tonsila do Cerebelo/citologia
Transtorno Bipolar/fisiopatologia
Hipocampo/citologia
Neuroglia/fisiologia
[Mh] Termos MeSH secundário: Tonsila do Cerebelo/metabolismo
Tonsila do Cerebelo/patologia
Astrócitos/metabolismo
Astrócitos/patologia
Transtorno Bipolar/tratamento farmacológico
Encéfalo/patologia
Encéfalo/fisiopatologia
Diagnóstico
Fator Neurotrófico Derivado de Linhagem de Célula Glial/metabolismo
Hipocampo/metabolismo
Hipocampo/patologia
Seres Humanos
Transtornos do Humor/tratamento farmacológico
Neuroglia/citologia
Neuroglia/metabolismo
Neurônios/metabolismo
Neurônios/patologia
Oligodendroglia/metabolismo
Oligodendroglia/patologia
Subunidade beta da Proteína Ligante de Cálcio S100/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (GDNF protein, human); 0 (Glial Cell Line-Derived Neurotrophic Factor); 0 (S100 Calcium Binding Protein beta Subunit); 0 (S100B protein, human)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1017/neu.2016.56


  4 / 2322 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:29186242
[Au] Autor:Salem SAM; El-Khateeb EA; Harvy M; Emam HME; Abdelaal W; Nemr RE; El-Hagry OO
[Ad] Endereço:Department of Dermatology and Venereology, Ain Shams University - Cairo, Egypt.
[Ti] Título:Study of serum levels and skin expression of S100B protein in psoriasis.
[So] Source:An Bras Dermatol;92(3):323-328, 2017 May-Jun.
[Is] ISSN:1806-4841
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: S100B protein was reported to be elevated in psoriatic patients' serum, with no previous evaluation of its skin expression, in contrast to the extensively studied S100 protein. OBJECTIVE: To evaluate the serum level and skin expression of S100B in psoriasis to assess its possible involvement in its pathogenesis. METHODS: Serum level of S100B protein was estimated in 40 psoriatic patients of different clinical varieties and 10 healthy controls. S100B protein expression was assessed immunohistochemically in lesional and non-lesional skin of patients and in normal skin of controls. Relation to disease severity was also evaluated. RESULTS: Serum level of S100B protein was significantly higher in psoriatic patients (0.15±0.03 µg/l) than in controls (0.03±0.007 µg/l) (P-value <0.001) with no significant correlation with PASI score. On comparing grades of S100B protein skin expression in lesional and non-lesional skin biopsies, a statistically significant difference was found (P=0.046) with higher percentage of strong S100B skin expression (60%) in non-lesional than in lesional (42%) skin. All the control biopsies showed negative expression. STUDY LIMITATIONS: Relatively small sample size with a limited range of low PASI scores. CONCLUSION: This study points to a potential link between psoriasis and S100B protein with higher serum and skin expression in patients than in controls.
[Mh] Termos MeSH primário: Psoríase/sangue
Subunidade beta da Proteína Ligante de Cálcio S100/sangue
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Biomarcadores/sangue
Biópsia
Estudos de Casos e Controles
Criança
Ensaio de Imunoadsorção Enzimática
Feminino
Seres Humanos
Imuno-Histoquímica
Masculino
Meia-Idade
Psoríase/patologia
Índice de Gravidade de Doença
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (S100 Calcium Binding Protein beta Subunit); 0 (S100B protein, human)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180131
[Lr] Data última revisão:
180131
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171130
[St] Status:MEDLINE


  5 / 2322 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29095291
[Au] Autor:Alshweki A; Pérez-Muñuzuri A; López-Suárez O; Baña A; Couce ML
[Ad] Endereço:Neonatal Unit, Department of Pediatrics, Santiago de Compostela University Hospital, IDIS (Health Research Institute of Santiago de Compostela), CIBERER, Travesia Choupana, Santiago de Compostela, Spain.
[Ti] Título:Relevance of urinary S100B protein levels as a short-term prognostic biomarker in asphyxiated infants treated with hypothermia.
[So] Source:Medicine (Baltimore);96(44):e8453, 2017 Nov.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The initial diagnosis of neonatal hypoxic-ischemic encephalopathy is based on nervous system clinical manifestations. The use of biomarkers to monitor brain injury and evaluate neuroprotective effects allows early intervention and treatment. This study was designed to determine the short-term prognostic significance of urinary S100B calcium-binding protein (S100B) in asphyxiated newborns treated with hypothermia.An observational prospective study was conducted over a period of 5 years in 31 newborns with hypoxic-ischemic encephalopathy who received therapeutic hypothermia. The patients were divided into 2 groups: Group A (13 newborns with a normal neurological examination before discharge) and Group B (18 newborns who died during admission or had an abnormal neurologic examination before discharge). Urinary S100B was the main variable, serum S100B and neuron-specific enolase (NSE) were considered as secondary variables, and all of them were assessed on the first 3 days of life. The newborns were subsequently divided into groups with normal and abnormal electrophysiological and imaging findings.Mean urinary S100B levels were significantly higher in group B than group A on day 1 (10.58 ±â€Š14.82 vs 4.65 ±â€Š9.16 µg/L, P = .031) and day 2 (5.16 ±â€Š7.63 vs 0.88 ±â€Š2.53, P = .002). The optimal cutoff for urinary S100B on day 1 was >1.11 µg/L of (sensitivity, 100%; specificity 60%) for the prediction of neonatal death and < 0.66 µg/L (sensitivity 83% and specificity 70%) for the prediction of a normal neurological examination before discharge. It was not possible to calculate cutoffs with a similar accuracy for serum S100B or NSE. Urinary S100B on day 1 was higher in patients with abnormal magnetic resonance imaging findings (7.89 ±â€Š8.09 vs 4.49 ±â€Š9.14, P = .039) and abnormal positron emission tomography findings (8.60 ±â€Š9.29 vs 4.30 ±â€Š8.28, P = .038). There were no significant differences in S100B levels between patients with normal and abnormal electroencephalography results.Urinary S100B measured in the first days of life can predict neonatal death and short-term prognosis in asphyxiated newborns treated with hypothermia. The method is convenient, noninvasive, and has a higher sensitivity and specificity than measurement of serum S100B or NSE.
[Mh] Termos MeSH primário: Hipotermia Induzida/métodos
Hipóxia-Isquemia Encefálica/urina
Subunidade beta da Proteína Ligante de Cálcio S100/urina
[Mh] Termos MeSH secundário: Biomarcadores/sangue
Biomarcadores/urina
Eletroencefalografia
Feminino
Seres Humanos
Hipóxia-Isquemia Encefálica/sangue
Hipóxia-Isquemia Encefálica/terapia
Recém-Nascido
Masculino
Exame Neurológico/métodos
Morte Perinatal/etiologia
Fosfopiruvato Hidratase/sangue
Prognóstico
Estudos Prospectivos
Subunidade beta da Proteína Ligante de Cálcio S100/sangue
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Biomarkers); 0 (S100 Calcium Binding Protein beta Subunit); 0 (S100B protein, human); EC 4.2.1.11 (Phosphopyruvate Hydratase)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171103
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008453


  6 / 2322 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28858130
[Au] Autor:Cao YH; Chi P; Zhao YX; Dong XC
[Ad] Endereço:aDepartment of Anesthesiology, Beijing YouAn Hospital, Capital Medical University bDepartment of Anesthesiology,Guang'anmen Hospital, China Acadamy of Chinese Medical Science, Beijing, China.
[Ti] Título:Effect of bispectral index-guided anesthesia on consumption of anesthetics and early postoperative cognitive dysfunction after liver transplantation: An observational study.
[So] Source:Medicine (Baltimore);96(35):e7966, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The objective of this study was to summarize the incidence of postoperative cognitive dysfunction (POCD) after 7days following liver transplantation (LT), and to evaluate the effectiveness of bispectral index (BIS) guided anesthetic intervention in reducing POCD. Additional serum concentrations of S100ß and neuron-specific enolase (NSE) were detected during surgery to determine whether they were reliable predictors of POCD.Patients who underwent LT at Beijing YouAn Hospital Affiliated to Capital University of Medical Science from January 2014 to December 2015 were enrolled. BIS monitor was needed during surgery. Patients who underwent LT without BIS monitoring during August 2012 to December 2014 served as historical controls. A battery of 5 neuropsychological tests were performed and scored preoperatively and 7days after surgery. POCD was diagnosed by the method of one standard deviation (SD). The blood samples of BIS group were collected at 5 time points: just before induction of general anesthesia (T0), 60 minutes after skin incision (T1), 30 minutes after the start of the anhepatic phase (T2), 15 minutes after reperfusion of the new liver (T3), and at 24 hours after surgery (T4).A total of 33 patients were included in BIS group, and 27 in the control group. Mean arterial pressure was different between 2 groups at 30 minutes after the start of the anhepatic phase (P = .032). The dose of propofol using at anhepatic phase 30 min and new liver 15 min was lower in the BIS group than control group (0.042 ±â€Š0.021 vs. 0.069 ±â€Š0.030, P < .001; 0.053 ±â€Š0.022 vs. 0.072 ±â€Š0.020, P = .001). Five patients were diagnosed as having POCD after 7 days in the BIS group and the incidence of POCD was 15.15%. In the control group, 9 patients had POCD and the incidence of POCD was 33.33%. The incidence of POCD between 2 groups had no statistical difference (P = .089). S100ß increased at stage of anhepatic 30 minutes (T2) and new liver 15 minutes (T3) compared with the stage of before anesthesia (T0) (1.49 ±â€Š0.66 vs. 0.72 ±â€Š0.53, P < .001; 1.92 ±â€Š0.78 vs. 0.72 ±â€Š0.53, P < .001). NSE increased at stage of anhepatic 30 minutes (T2) and new liver 15 minutes (T3) compared with the stage of before anesthesia (T0) (5.80 ±â€Š3.03 vs. 3.58 ±â€Š3.24, P = .001; 10.04 ±â€Š5.65 vs. 3.58 ±â€Š3.24, P < .001). At 24 hours after surgery, S100ß had no difference compared to one before anesthesia (1.0 ±â€Š0.62 vs. 0.72 ±â€Š0.53, P = .075), but NSE still remained high (5.19 ±â€Š3.64 vs. 3.58 ±â€Š3.24, P = .043). There were no significant differences in the serum concentrations of S100ß between patients with and without POCD at 5 time points of operation (P > .05). But at 24 hours after surgery, NSE concentrations were still high of patients with POCD (8.14 ±â€Š3.25 vs. 4.81 ±â€Š3.50, P = .035).BIS-guided anesthesia can reduce consumption of propofol during anhepatic and new liver phase. Patients in BIS group seem to have a mild lower incidence of POCD compared to controls, but no statistical significant. The influence of BIS-guided anesthesia on POCD needs to be further confirmed by large-scale clinical study. S100ß protein and NSE are well correlative with neural injury, but NSE is more suitable for assessment of incidence of postoperative cognitive deficits after surgery.
[Mh] Termos MeSH primário: Anestesia Intravenosa/métodos
Anestésicos Intravenosos/administração & dosagem
Disfunção Cognitiva/diagnóstico
Disfunção Cognitiva/prevenção & controle
Transplante de Fígado/efeitos adversos
Complicações Pós-Operatórias/diagnóstico
Complicações Pós-Operatórias/prevenção & controle
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Masculino
Meia-Idade
Testes Neuropsicológicos
Fosfopiruvato Hidratase/sangue
Propofol/administração & dosagem
Subunidade beta da Proteína Ligante de Cálcio S100/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Anesthetics, Intravenous); 0 (S100 Calcium Binding Protein beta Subunit); EC 4.2.1.11 (Phosphopyruvate Hydratase); YI7VU623SF (Propofol)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170901
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007966


  7 / 2322 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28797756
[Au] Autor:Damude S; Wevers KP; Murali R; Kruijff S; Hoekstra HJ; Bastiaannet E
[Ad] Endereço:Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, The Netherlands. Electronic address: s.damude@umcg.nl.
[Ti] Título:A prediction tool incorporating the biomarker S-100B for patient selection for completion lymph node dissection in stage III melanoma.
[So] Source:Eur J Surg Oncol;43(9):1753-1759, 2017 Sep.
[Is] ISSN:1532-2157
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Completion lymph node dissection (CLND) in sentinel node (SN)-positive melanoma patients is accompanied with morbidity, while about 80% yield no additional metastases in non-sentinel nodes (NSNs). A prediction tool for NSN involvement could be of assistance in patient selection for CLND. This study investigated which parameters predict NSN-positivity, and whether the biomarker S-100B improves the accuracy of a prediction model. METHODS: Recorded clinicopathologic factors were tested for their association with NSN-positivity in 110 SN-positive patients who underwent CLND. A prediction model was developed with multivariable logistic regression, incorporating all predictive factors. Five models were compared for their predictive power by calculating the Area Under the Curve (AUC). A weighted risk score, 'S-100B Non-Sentinel Node Risk Score' (SN-SNORS), was derived for the model with the highest AUC. Besides, a nomogram was developed as visual representation. RESULTS: NSN-positivity was present in 24 (21.8%) patients. Sex, ulceration, number of harvested SNs, number of positive SNs, and S-100B value were independently associated with NSN-positivity. The AUC for the model including all these factors was 0.78 (95%CI 0.69-0.88). SN-SNORS was the sum of scores for the five parameters. Scores of ≤9.5, 10-11.5, and ≥12 were associated with low (0%), intermediate (21.0%) and high (43.2%) risk of NSN involvement. CONCLUSIONS: A prediction tool based on five parameters, including the biomarker S-100B, showed accurate risk stratification for NSN-involvement in SN-positive melanoma patients. If validated in future studies, this tool could help to identify patients with low risk for NSN-involvement.
[Mh] Termos MeSH primário: Excisão de Linfonodo
Melanoma/sangue
Melanoma/cirurgia
Subunidade beta da Proteína Ligante de Cálcio S100/sangue
Neoplasias Cutâneas/sangue
Neoplasias Cutâneas/cirurgia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Área Sob a Curva
Biomarcadores Tumorais/sangue
Criança
Pré-Escolar
Feminino
Seres Humanos
Modelos Logísticos
Linfonodos/patologia
Metástase Linfática
Masculino
Melanoma/secundário
Meia-Idade
Estadiamento de Neoplasias
Nomogramas
Seleção de Pacientes
Valor Preditivo dos Testes
Curva ROC
Medição de Risco/métodos
Fatores Sexuais
Neoplasias Cutâneas/patologia
Úlcera Cutânea/etiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (S100 Calcium Binding Protein beta Subunit)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170812
[St] Status:MEDLINE


  8 / 2322 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28716979
[Au] Autor:Bustamante A; López-Cancio E; Pich S; Penalba A; Giralt D; García-Berrocoso T; Ferrer-Costa C; Gasull T; Hernández-Pérez M; Millan M; Rubiera M; Cardona P; Cano L; Quesada H; Terceño M; Silva Y; Castellanos M; Garces M; Reverté S; Ustrell X; Marés R; Baiges JJ; Serena J; Rubio F; Salas E; Dávalos A; Montaner J
[Ad] Endereço:From the Neurovascular Research Laboratory, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain (A.B., A.P., D.G., T.G.-B., J.M.); Stroke Unit, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain (E.L.-C., M.H.-P., M.M., A
[Ti] Título:Blood Biomarkers for the Early Diagnosis of Stroke: The Stroke-Chip Study.
[So] Source:Stroke;48(9):2419-2425, 2017 Sep.
[Is] ISSN:1524-4628
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND PURPOSE: Stroke diagnosis could be challenging in the acute phase. We aimed to develop a blood-based diagnostic tool to differentiate between real strokes and stroke mimics and between ischemic and hemorrhagic strokes in the hyperacute phase. METHODS: The Stroke-Chip was a prospective, observational, multicenter study, conducted at 6 Stroke Centers in Catalonia. Consecutive patients with suspected stroke were enrolled within the first 6 hours after symptom onset, and blood samples were drawn immediately after admission. A 21-biomarker panel selected among previous results and from the literature was measured by immunoassays. Outcomes were differentiation between real strokes and stroke mimics and between ischemic and hemorrhagic strokes. Predictive models were developed by combining biomarkers and clinical variables in logistic regression models. Accuracy was evaluated with receiver operating characteristic curves. RESULTS: From August 2012 to December 2013, 1308 patients were included (71.9% ischemic, 14.8% stroke mimics, and 13.3% hemorrhagic). For stroke versus stroke mimics comparison, no biomarker resulted included in the logistic regression model, but it was only integrated by clinical variables, with a predictive accuracy of 80.8%. For ischemic versus hemorrhagic strokes comparison, NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) >4.9 (odds ratio, 2.40; 95% confidence interval, 1.55-3.71; <0.0001) and endostatin >4.7 (odds ratio, 2.02; 95% confidence interval, 1.19-3.45; =0.010), together with age, sex, blood pressure, stroke severity, atrial fibrillation, and hypertension, were included in the model. Predictive accuracy was 80.6%. CONCLUSIONS: The studied biomarkers were not sufficient for an accurate differential diagnosis of stroke in the hyperacute setting. Additional discovery of new biomarkers and improvement on laboratory techniques seem necessary for achieving a molecular diagnosis of stroke.
[Mh] Termos MeSH primário: Isquemia Encefálica/sangue
Hemorragia Cerebral/sangue
Acidente Vascular Cerebral/sangue
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Amina Oxidase (contendo Cobre)/sangue
Apolipoproteína C-III/sangue
Biomarcadores/sangue
Isquemia Encefálica/diagnóstico
Estudos de Casos e Controles
Caspase 3/sangue
Moléculas de Adesão Celular/sangue
Hemorragia Cerebral/diagnóstico
Quimiocina CXCL1/sangue
Endostatinas/sangue
Proteína Ligante Fas/sangue
Feminino
Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo
Fibronectinas/sangue
Proteínas de Choque Térmico HSC70/sangue
Seres Humanos
Proteína 3 de Ligação a Fator de Crescimento Semelhante à Insulina/sangue
Subunidade gama Comum de Receptores de Interleucina/sangue
Interleucina-17/sangue
Interleucina-6/sangue
Modelos Logísticos
Masculino
Metaloproteinase 9 da Matriz/sangue
Meia-Idade
Peptídeo Natriurético Encefálico/sangue
Fator de Crescimento Neural/sangue
Moléculas de Adesão de Célula Nervosa/sangue
Razão de Chances
Fragmentos de Peptídeos/sangue
Fosfopiruvato Hidratase/sangue
Estudos Prospectivos
Curva ROC
Receptores Tipo I de Fatores de Necrose Tumoral/sangue
Subunidade beta da Proteína Ligante de Cálcio S100/sangue
Acidente Vascular Cerebral/diagnóstico
Fator de von Willebrand/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Apolipoprotein C-III); 0 (Biomarkers); 0 (Cell Adhesion Molecules); 0 (Chemokine CXCL1); 0 (Endostatins); 0 (FASLG protein, human); 0 (Fas Ligand Protein); 0 (Fibrin Fibrinogen Degradation Products); 0 (Fibronectins); 0 (HSC70 Heat-Shock Proteins); 0 (HSPA8 protein, human); 0 (IGFBP3 protein, human); 0 (IL17A protein, human); 0 (IL2RG protein, human); 0 (IL6 protein, human); 0 (Insulin-Like Growth Factor Binding Protein 3); 0 (Interleukin Receptor Common gamma Subunit); 0 (Interleukin-17); 0 (Interleukin-6); 0 (NGF protein, human); 0 (Neural Cell Adhesion Molecules); 0 (Peptide Fragments); 0 (Receptors, Tumor Necrosis Factor, Type I); 0 (S100 Calcium Binding Protein beta Subunit); 0 (S100B protein, human); 0 (fibrin fragment D); 0 (pro-brain natriuretic peptide (1-76)); 0 (von Willebrand Factor); 114471-18-0 (Natriuretic Peptide, Brain); 9061-61-4 (Nerve Growth Factor); EC 1.4.3.21 (AOC3 protein, human); EC 1.4.3.21 (Amine Oxidase (Copper-Containing)); EC 3.4.22.- (CASP3 protein, human); EC 3.4.22.- (Caspase 3); EC 3.4.24.35 (MMP9 protein, human); EC 3.4.24.35 (Matrix Metalloproteinase 9); EC 4.2.1.11 (Phosphopyruvate Hydratase)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170719
[St] Status:MEDLINE
[do] DOI:10.1161/STROKEAHA.117.017076


  9 / 2322 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28662512
[Au] Autor:Dong L; Wang S; Li Y; Zhao Z; Shen Y; Liu L; Xu G; Ma C; Li S; Zhang X; Cong B
[Ad] Endereço:Department of Forensic Medicine, Basic Medical College, Hebei Medical University, Hebei Key Laboratory of Forensic Medicine, Shijiazhuang, China.
[Ti] Título:RU486 Reverses Emotional Disorders by Influencing Astrocytes and Endoplasmic Reticulum Stress in Chronic Restraint Stress Challenged Rats.
[So] Source:Cell Physiol Biochem;42(3):1098-1108, 2017.
[Is] ISSN:1421-9778
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:AIMS: To investigate the effect of RU486 (mifepristone) on emotional disorders in chronic restraint stress-induced rats and to explore the mechanisms of that phenomenon. METHODS: For this purpose, 80 healthy male Sprague Dawley rats were randomly divided into four groups: the normal group (Con group, The Con group members received no treatment, eating and drinking freely), the chronic restraint stress group (CRS group, normal Sprague Dawley rats treated with chronic restraint stress, 6 h/day for 21days), the propylene glycol group (CRS+propylene glycol) and the RU486 group (CRS+RU486). RU486 or propylene glycol was administered 30 mins before each CRS procedure. Twenty-four hours after CRS exposure, we investigated the effects of CRS on the anxiety-like behavior using an elevated plus-maze (EPM). To explore the mechanisms of RU486 on anxiety, we measured the expression of glial fibrillary acid protein (GFAP) and ß-subunit of S100 (S100ß) via immunohistochemistry and western blot analysis. Apoptosis was demonstrated by flow cytometry. In addition, endoplasmic reticulum (ER) stress markers, glucose regulated protein 78 (GRP78), C/EBP homologous protein (CHOP) and Cysteine aspartic acid specific protease-12 (Caspase-12), were detected by western blot analysis. RESULTS: Compared to the control group, rats in the CRS and propylene glycol group showed decreased exploratory behavior on the open arms during EPM testing, and these reductions were accompanied by significantly reduced GFAP and S100ß expression, increased apoptosis and GRP78, CHOP, and caspase-12 expression in the amygdala. However, RU486 increases the exploratory behavior and reverses the changes of GFAP, S100ß, GRP78, CHOP, and caspase-12 and protects cells against apoptosis. CONCLUSIONS: Taken together, these data suggest that exposure to chronic restraint stress decreases the number of astrocytes and induces apoptosis and ER stress in the amygdala, which are possible causes for psychiatric disorders. RU486 can significantly ameliorate abnormal behaviors in CRS-induced anxiety model rats. The protective effects of RU486 could be attributed to its anti-ER stress, anti-apoptosis and astrocyte increasing effects.
[Mh] Termos MeSH primário: Ansiedade/tratamento farmacológico
Astrócitos/efeitos dos fármacos
Estresse do Retículo Endoplasmático/efeitos dos fármacos
Antagonistas de Hormônios/uso terapêutico
Mifepristona/uso terapêutico
Estresse Psicológico/tratamento farmacológico
[Mh] Termos MeSH secundário: Tonsila do Cerebelo/efeitos dos fármacos
Tonsila do Cerebelo/metabolismo
Tonsila do Cerebelo/patologia
Animais
Ansiedade/metabolismo
Ansiedade/patologia
Astrócitos/metabolismo
Astrócitos/patologia
Proteína Glial Fibrilar Ácida/análise
Proteína Glial Fibrilar Ácida/metabolismo
Masculino
Ratos Sprague-Dawley
Subunidade beta da Proteína Ligante de Cálcio S100/análise
Subunidade beta da Proteína Ligante de Cálcio S100/metabolismo
Estresse Psicológico/metabolismo
Estresse Psicológico/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glial Fibrillary Acidic Protein); 0 (Hormone Antagonists); 0 (S100 Calcium Binding Protein beta Subunit); 0 (S100b protein, rat); 0 (glial fibrillary acid protein, rat); 320T6RNW1F (Mifepristone)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170630
[St] Status:MEDLINE
[do] DOI:10.1159/000478764


  10 / 2322 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28658163
[Au] Autor:Zhang Q; Li YN; Guo YY; Yin CP; Gao F; Xin X; Huo SP; Wang XL; Wang QJ
[Ad] Endereço:Department of Anesthesiology, the Third Hospital of Hebei Medical University, No.139, Ziqiang Road, Shijiazhuang City, Hebei, China.
[Ti] Título:Effects of preconditioning of electro-acupuncture on postoperative cognitive dysfunction in elderly: A prospective, randomized, controlled trial.
[So] Source:Medicine (Baltimore);96(26):e7375, 2017 Jun.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Electro-acupuncture is a burgeoning treatment using the needle inserting into the body acupoints and the low-frequency pulse current being electrified by an electric acupuncture machine. This study was designed to evaluate the effects of preconditioning of electro-acupuncture on postoperative cognitive dysfunction in elderly.Ninety patients scheduled spine surgery were randomly assigned into 2 groups using a random number table: control group (group C) and electro-acupuncture group (group EA). In group EA, electro-acupuncture was applied on Baihui, Dazhui, and Zusanli acupoints 30 minutes before anesthesia. At 0 minute before treatment of electro-acupuncture, 1 hour after skin incision and surgery completed (T1-3), blood samples were taken for detection of interleukin (IL)-6, IL-10, and S100ß by enzyme-linked immunosorbent assay. The total dose of remifentanil and propofol during surgery were recorded. Mini-Mental State Examination was applied to evaluate the cognitive function of patients at 1 day before surgery and 7th and 30th day after surgery.The results showed that compared with group C, score of MMSE increased after surgery, the serum concentration of IL-6, IL-10, and S100ß decreased at 1 hour after skin incision, and surgery completed in group EA. Moreover, the total dose of remifentanil and propofol reduced during surgery in group EA.The present study suggests that preconditioning of electro-acupuncture could improve the postoperative cognitive function, and the reduction of inflammatory reaction and brain injury may be involved in the mechanism.
[Mh] Termos MeSH primário: Disfunção Cognitiva/etiologia
Disfunção Cognitiva/prevenção & controle
Eletroacupuntura
Complicações Pós-Operatórias/prevenção & controle
Cuidados Pré-Operatórios
Coluna Vertebral/cirurgia
[Mh] Termos MeSH secundário: Idoso
Anestésicos Intravenosos/uso terapêutico
Biomarcadores/sangue
Disfunção Cognitiva/sangue
Feminino
Seres Humanos
Interleucina-10/sangue
Interleucina-6/sangue
Masculino
Entrevista Psiquiátrica Padronizada
Duração da Cirurgia
Procedimentos Ortopédicos
Piperidinas/uso terapêutico
Complicações Pós-Operatórias/sangue
Complicações Pós-Operatórias/psicologia
Propofol/uso terapêutico
Subunidade beta da Proteína Ligante de Cálcio S100/sangue
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anesthetics, Intravenous); 0 (Biomarkers); 0 (IL10 protein, human); 0 (IL6 protein, human); 0 (Interleukin-6); 0 (Piperidines); 0 (S100 Calcium Binding Protein beta Subunit); 0 (S100B protein, human); 130068-27-8 (Interleukin-10); P10582JYYK (remifentanil); YI7VU623SF (Propofol)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170718
[Lr] Data última revisão:
170718
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170629
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007375



página 1 de 233 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde